Fluoroquinolone consumption and -resistance trends in Mycobacterium tuberculosis and other respiratory pathogens: Ecological antibiotic pressure and consequences in Pakistan, 2009–2015

Shakoor, Sadia; Tahseen, Sabira; Jabeen, Kauser; Fatima, Razia; Malik, Faisal; Rizvi, Alamdar Hussain; Hasan, Rumina

doi:10.1016/j.ijmyco.2016.07.008

Cited by 10 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instead, as shown by comparison between two subgroups of patients treated for over 6 months, fluoroquinolone use can slightly increase the prevalence of fluoroquinolone resistance. A similar weak relationship between fluoroquinolone resistance and fluoroquinolone consumption for M. tuberculosis has been demonstrated previously [15].…”

Section: @Erspublicationssupporting

confidence: 85%

Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use

et al. 2017

View full text Add to dashboard Cite

Section: @Erspublicationssupporting

confidence: 85%

Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use

et al. 2017

View full text Add to dashboard Cite

“…12,13 Many other studies from different regions have also demonstrated weak relationship between prior FQ use and FQ resistance. [14][15][16] The correlation between resistance to a drug (other than rifampicin and isoniazid) and prior intake of the same drug was not found to be statistically significant for any drug. According to a study by Hamusse et al, individuals with previous history of TB treatment were eight times more likely to develop resistance to any first-line anti-TB drugs compared to those with no history of previous TB treatment.…”

Section: Discussionmentioning

confidence: 99%

Drug resistance profile among multi-drug resistant tuberculosis patients at diagnosis and correlation with history of anti-tubercular treatment in a tertiary care center

et al. 2019

View full text Add to dashboard Cite

Background: Drug Resistant Tuberculosis (DR-TB) is a major threat to the realization of the goal of a TB free world in the near future. It is important to study the reasons for the increasing number of such cases so that effective action can be taken to control this growing epidemic.Methods: Sputum from 36 patients diagnosed with acquired pulmonary Multidrug Resistant Tuberculosis (MDR-TB) were subjected to first- and second-line Drug Sensitivity Testing (DST) after liquid culture in mycobacterium growth Indicator Tube (MGIT). Primary MDR-TB cases were excluded. The relation of the drug sensitivity profile with the history of prior treatment taken was statistically analysed.Results: Majority of the patients had received appropriate treatment, and most had adhered to prescribed treatment. Among the 36 patients, 24(66.7%) were found to be Pre-Extensively Drug Resistant (Pre-XDR-TB) and 4(11.1%) were extensively drug resistant XDR-TB cases. Inappropriate prescription of fluoroquinolone (FQ) was found to be most common. Prior intake of any drug was not found to significantly affect subsequent resistance to that drug.Conclusions: Fluoroquinolone resistance is quite common in patients with DR-TB (66.7%). This study did not find the prior use of FQ or any other drug to significantly affect subsequent resistance to the drug. Primary drug resistance is thus a major concern. 11.1% patients were found to be XDR-TB cases. Hence DST for first- and second-line drugs should be done at the time of diagnosis to avoid failure of treatment with a predesigned regimen.

show abstract

“…Sparfloxacin has shown an efficient and safe alternative in treating complex TB and is the only appropriate substitute drug at present to treat some cases of MDR‐TB. [ 50 ] Sokolova et al, have studied the efficiency and safety of sparfloxacin in combination therapy for drug‐susceptible and drug‐resistant pulmonary TB through enrolling 60 members with severe pulmonary‐TB. Sparfloxacin was combined with other anti‐TB drugs to create highly effective combinations.…”

Section: Advances In Preclinical Developmentmentioning

confidence: 99%

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Reddy

Sinha

Kumar

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

The prevalence of tuberculosis (TB) remains the leading cause of death from a single infectious agent, ranking it above all other contagious diseases. The problem to tackle this disease seems to become even worse due to the outbreak of SARS-CoV-2.Further, the complications related to drug-resistant TB, prolonged treatment regimens, and synergy between TB and HIV are significant drawbacks. There are several drugs to treat TB, but there is still no rapid and accurate treatment available.Intensive research is, therefore, necessary to discover newer molecular analogs that can probably eliminate this disease within a short span. An increase in efficacy can be achieved through re-engineering old TB-drug families and repurposing known drugs.These two approaches have led to the production of newer classes of compounds with novel mechanisms to treat multidrug-resistant strains. With respect to this context, we discuss structural aspects of developing new anti-TB drugs as well as examine advances in TB drug discovery. It was found that the fluoroquinolone, oxazolidinone, and nitroimidazole classes of compounds have greater potential to be further explored for TB drug development. Most of the TB drug candidates in the clinical phase are modified versions of these classes of compounds. Therefore, here we anticipate that modification or repurposing of these classes of compounds has a higher probability to reach the clinical phase of drug development. The information provided will pave the way for researchers to design and identify newer molecular analogs for TB drug development and also broaden the scope of exploring future-generation potent, yet safer anti-TB drugs.

show abstract

Fluoroquinolone consumption and -resistance trends in Mycobacterium tuberculosis and other respiratory pathogens: Ecological antibiotic pressure and consequences in Pakistan, 2009–2015

Abstract: We discuss the possible reasons for the decrease in resistance rates in TB, putative drivers of resistance other than volume of FQ consumption, and the possible impact of the National Tuberculosis Programme and drug regulatory activities.

Cited by 10 publications

References 13 publications

Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use

Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use

Drug resistance profile among multi-drug resistant tuberculosis patients at diagnosis and correlation with history of anti-tubercular treatment in a tertiary care center

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Contact Info

Product

Resources

About